| Ytd | 55.25% | |
| 1y | 55.17% |
| Open | 28.71 | Prev Close | 28.50 | Low | 28.64 | High | 29.44 | Mkt Cap | 1.51B |
| Vol | 709.28K | Avg Vol | 821.03K | EPS | -0.16 | P/E | N/A | Forward P/E | 25.79 |
| Beta | 2.48 | Short Ratio | 11.22 | Inst. Own | 101.81% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-28 | 50-d Avg | 22.79 | 200-d Avg | 18.91 | 1yr Est | 25.80 |
CDNA News
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnos
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading
The CEO sold 17,683 shares for a transaction value of approximately ~$425,000 at a weighted average
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading
On June 16, 2026, CareDx Inc (CDNA) shares fell by 3.4% to a current price of $23.22. The stock has
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading
CareDx NASDAQ: CDNA executives outlined the company's strategy to focus on precision diagnostics, ex
CareDx, Inc. (CDNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcri
In the first quarter of 2026, Baron Discovery Fund declined 10.65% (Institutional Shares), trailing
CareDx NASDAQ: CDNA executives outlined the company's growth strategy, first-quarter performance and
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading
CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused o
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading
CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leadin
CareDx (CDNA) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estim
CareDx, Inc.Common StockPreferred StockDebt SecuritiesWarrantsSubscription RightsUnitsWe may offer
CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused o
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading
CareDx (NASDAQ:CDNA) raises FY2026 sales outlook from $420.000 million-$444.000 million to $447.000
CareDx (NASDAQ:CDNA) reported quarterly earnings of $0.34 per share which beat the analyst consensus
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading
CDNA unveils AlloSeq Nano, delivering high-resolution HLA typing in under 3 hours, aiming to boost t
CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused o
CareDx Inc. (CDNA) sells Lab Products business to EuroBio Scientific for $170 million in cash, focus
U.S. stocks were mixed on Thursday, with the Dow Jones gaining 0.1%. Aehr Test Systems shares rose 1
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused
Wells Fargo analyst Brandon Couillard maintains CareDx (NASDAQ:CDNA) with a Equal-Weight and rais
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
CareDx (NASDAQ:CDNA) reported quarterly earnings of $0.12 per share which missed the analyst consens
CareDx (NASDAQ:CDNA) raises FY2025 sales outlook from $372.000 million-$376.000 million to $380.000
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused
Wells Fargo analyst Brandon Couillard maintains CareDx (NASDAQ:CDNA) with a Equal-Weight and rais
CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, develop
